The Episealer® implant highlighted in three scientific publications
Episurf Medical AB’s (NASDAQ: EPIS B) Episealer® knee implant has recently been discussed in three peer-reviewed scientific publications. All three publications; “Current surgical options for the treatment of symptomatic articular cartilage lesions of the knee” (Biant, L.C. et al., Orthopaedics and Trauma, 2019. 33(2): 127-132), “Focal knee resurfacing” (Nahas, S., et al., Orthopaedics and Trauma, 2019. 33(2): 133-139) and “What future in the treatment of osteochondral knee defects?” (D’Ambrosi, R., et al., Annals of Translational Medicine, 2018, 6, Suppl 2, S100) discuss various treatment alternatives for patients in the so-called treatment gap, where the patient typically is too old for conservative biological treatment, but not yet a candidate for knee replacement surgery. In all of these publications various treatment alternatives are discussed and the Episealer® is highlighted as a promising technology for the future given its early clinical success and low revision rate.
“It is highly interesting that these publications are published just recently. We are experiencing an increasing interest in the gap patients as new technologies offer new treatment options. We intend to be a leader in this market segment. It is also encouraging that the lack of a golden standard in the treatment algorithm is highlighted in scientific publications. Our strategy is designed for taking a leading role in this development, and our goal is to establish Episealer® as a standardised treatment alternative. These publications again emphasise the fact that this is an unmet clinical need, and our opinion is that Episealer® can make a significant difference for these patients” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] =>
[HtmlContact:protected] =>
[HtmlTitle:protected] => <h1 style="font-family: arial,helvetica,sans-serif;">The Episealer® implant highlighted in three scientific publications</h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[Body:protected] => Episurf Medical AB’s (NASDAQ: EPIS B) Episealer® knee implant has recently been discussed in three peer-reviewed scientific publications. All three publications; “Current surgical options for the treatment of symptomatic articular cartilage lesions of the knee” (Biant, L.C. et al., Orthopaedics and Trauma, 2019. 33(2): 127-132), “Focal knee resurfacing” (Nahas, S., et al., Orthopaedics and Trauma, 2019. 33(2): 133-139) and “What future in the treatment of osteochondral knee defects?” (D’Ambrosi, R., et al., Annals of Translational Medicine, 2018, 6, Suppl 2, S100) discuss various treatment alternatives for patients in the so-called treatment gap, where the patient typically is too old for conservative biological treatment, but not yet a candidate for knee replacement surgery. In all of these publications various treatment alternatives are discussed and the Episealer® is highlighted as a promising technology for the future given its early clinical success and low revision rate.
“It is highly interesting that these publications are published just recently. We are experiencing an increasing interest in the gap patients as new technologies offer new treatment options. We intend to be a leader in this market segment. It is also encouraging that the lack of a golden standard in the treatment algorithm is highlighted in scientific publications. Our strategy is designed for taking a leading role in this development, and our goal is to establish Episealer® as a standardised treatment alternative. These publications again emphasise the fact that this is an unmet clinical need, and our opinion is that Episealer® can make a significant difference for these patients” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
[HtmlBody:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">Episurf Medical AB</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">’s</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> (NASDAQ: EPIS B) </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">Episealer® </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">knee </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">implant</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> has recently been discussed in three peer-reviewed </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">scientific</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"> </span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">publications. All three publications</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">;</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> “</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">Current surgical options for the treatment of symptomatic articular cartilage lesions of the knee</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">” (</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">Biant</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">, L.C. </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">et al.</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">, </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">Orthopaedics</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> and Trauma, 2019. 33(2): 127-132</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">)</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">, “</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">Focal knee resurfacing</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">”</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"> </span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">(</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">Nahas</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">, S., et al., </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">Orthopaedics</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> and Trauma, 2019. 33(2): 133-139</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">)</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"> </span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">and “</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">What future in the treatment of osteochondral knee defects</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">?” (</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">D’Ambrosi</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">, R., </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">et al.</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">, Annals of Translational Medicine, </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">2018, 6, Suppl 2, S100</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">)</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> discuss various treatment alternatives </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">for patients in the so-called treatment gap, where the patient typically is too old for conservative biological treatment, but not yet a candidate for knee replacement surgery</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">. </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">I</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">n </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">all of</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> these publications various treatment alternatives are discussed and the </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">Episealer® is highlighted as a promising technology for the future given its early clinical success and low revision rate. </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-ccp-props="{"201341983":0,"335559739":160,"335559740":259}"> </span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">“It is highly interesting that these </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">publications</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"> </span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">are published just recently. We are experiencing an increasing interest </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">in</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> the gap patients as new technologies offer new treatment options. We intend to be a leader in this market segment. It is also </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">encouraging that the lack of a golden standard in the treatment algorithm is highlighted in scientific publications. Our strategy is designed </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">for</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"> </span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">tak</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">ing</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> a leading role in this development</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">,</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> and our goal is to establish Episealer® as a </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">standardi</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">s</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">ed</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> treatment alternative. These </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">publications</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"> </span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">again </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">emphasi</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">s</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">e</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> the fact that this is an unmet </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">clinical</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"> </span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">need, and our opinion is that Episealer® can make a </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">significant </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto">difference for these </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">patients”</span></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> says Pål Ryfors, CEO Episurf Medical.</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-contrast="auto"> </span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;" data-ccp-props="{"201341983":0,"335559739":160,"335559740":259}"> </span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;"><strong>For more information, please contact:</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">Pål Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">Tel:</span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt; font-family: arial, helvetica, sans-serif;">Email: </span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;"><strong>About Episurf Medical</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></span></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 9309
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 9307
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] =>
[Contact:protected] =>
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/2787022/1024497.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => The Episealer® implant highlighted in three scientific publications
[Description:protected] => The Episealer® implant highlighted in three scientific publications
[CreateDate:protected] => 2019-04-11T12:45:05Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 3266151
[EncryptedId:protected] => FB6CAD9BA9F99CFA
[IsRegulatory:protected] =>
[PublishDate:protected] => 2019-04-11T12:45:00Z
[LastChangeDate:protected] => 2019-04-11T12:45:05Z
[Title:protected] => The Episealer® implant highlighted in three scientific publications
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/the-episealer-implant-highlighted-in-three-scientific-publications,c2787022
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)